

Small molecule inhibition of *Helicobacter pylori* glycosylation
Daniel Williams, 2019

Helicobacter pylori (*H. pylori*) is a bacterial pathogen in the human digestive tract that produces chronic stomach inflammation. It has been associated with both stomach ulcers and stomach cancer, which is the second most common cause of death from cancer in humans worldwide [1,2]. Currently, the recommended treatment of *H. pylori*

However, the efficacy of this treatment method has been found to be suboptimal in eradicating the bacteria due to the development of antimicrobial resistance [4] and deleterious effects on the host microbiome [5]. Therefore, new innovative alternative treatment methods are needed.

Previous work has identified certain *H. pylori* cell surface sugar-modified proteins, termed glycoproteins, as therapeutic targets due in part to the fact that they differ markedly from those found in human cells and certain of these glycoproteins have been found to be unique to *H. pylori*. The Dube lab natural biosynthetic pathways, to incorporate unnatural sugars into *H. pylori* cellular glycoproteins, while

Figure 1. Effects of small molecule inhibitors on *Helicobacter pylori* glycosylation assembly. A) Normal lipid carrier-mediated glycosylation assembly pathway. Glycosyltransferases (GTs) sequentially transfer nucleotide-activated monosaccharides one sugar at a time onto a lipid

References:

1. Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005), Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55: 74-108.
2. Suzuki, H., Iwasaki, E., Hibi T., (2009) *Helicobacter pylori* and gastric cancer. Gastric Cancer 12: 79-87
3. Malfertholm T., Vakil N., Kuipers E.J., (2007). *Helicobacter pylori*: Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. Gut, 56:6 772-781

4. Luther J, Higgins P, Schoenfeld P, Moayeddi P, Vakil N, Chey W. (2010) Empiric Quadruple vs. Triple Therapy for Primary Treatment of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. *Am J Gastroenterol*, 105 :65-73.
5. Rafii, F.; Sutherland, J. B.; Cerniglia, C. E., Effects of treatment with antimicrobial agents on the human colonic microflora. *Ther Clin Risk Manag* 2008, 4 (6), 1343-58.
6. Dube D.H., Bertozzi C.R., (2003), Metabolic oligosaccharide engineering as a tool for glycobiology. *Current Opinion in Chemical Biology*, 7(5): 616-625.
7. Kaewsapsak, P., Esonu, O. and Dube, D. H. (2013), Recruiting the Host's Immune System to Target *Helicobacter pylori*'s Surface Glycans. *ChemBioChem*, 14: 721-726.
8. Karrington I. (2015) Honors Project, Biochemistry Program, Bowdoin College: Development of a Cyclooctyne-based Photodynamic Antibiotic for *Helicobacter pylori*
9. Herman R. (2017) Honors Project, Biochemistry Program, Bowdoin College: Development of alkyne-based therapeutics for the eradication of pathogenic bacteria based on their distinctive glycans
10. Ellen M. Sletten and Carolyn R. Bertozzi., From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions *Accounts of Chemical Research* 2011 44 (9), 666-676
11. Herget, S.; Toukach, P. V.; Ranzinger, R.; Hull, W. E.; Knirel, Y. A.; von der Lieth, C. W., Statistical analysis of the Bacterial Carbohydrate Structure Data Base (BCSDB): characteristics and diversity of bacterial carbohydrates in comparison with mammalian glycans. *BMC Struct Biol* 2008, 8, 35.
12. Tra, V. N., Dube, D. H., Glycans in pathogenic bacteria--potential for targeted covalent therapeutics and imaging agents. *Chem Commun (Camb)* 2014, 50 (36), 4659-73.
13. Rubin, E. J.; Trent, M. S., Colonize, evade, flourish: how glyco-conjugates promote virulence of *Helicobacter pylori*. *Gut Microbes* 2013, 4 (6), 439-53.
14. Clark, E. L., Emmadi, M., Krupp, K. L., Podilapu, A. R., Helble, J. D., Kulkarni, S. S., and Dube, D. H. (2016) Development of rare bacterial monosaccharide analogs for metabolic glycan labeling in pathogenic bacteria. *ACS Chemical Biology* 11, 3365-3373
15. Gloster, T. M., and Vocadlo, D. J. (2012) Developing inhibitors of glycan processing enzymes as

21. Brown, J. R.; Fuster, M. M.; Li, R.; Varki, N.; Glass, C. A.; Esko, J. D., A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. *Clin Cancer Res* 2006, *12* (9), 2894-901.
22. Dube D. (2017) Grant Proposal, Department of Chemistry, Bowdoin College: Deciphering *Helicobacter pylori*